PULMOCODEINA PLUS

This brand name is authorized in Ecuador

Active ingredients

The drug PULMOCODEINA PLUS contains a combination of these active pharmaceutical ingredients (APIs):

1 Codeine
UNII GSL05Y1MN6 - CODEINE PHOSPHATE

Codeine is a centrally acting weak analgesic. Codeine exerts its effect through ฮผ opioid receptors, although codeine has low affinity for these receptors, and its analgesic effect is due to its conversion to morphine. Codeine, particularly in combination with other analgesics such as paracetamol, has been shown to be effective in acute nociceptive pain. The anti-tussive activity of codeine is probably due to its depressant effect on the medullary cough centre in the brain.

Read about Codeine
2 Guaifenesin
UNII 495W7451VQ - GUAIFENESIN

Guaifenesin is an expectorant the action of which promotes or facilitates the removal of secretions from the respiratory tract. The precise mechanism of action of guaifenesin is not known; however, it is thought to act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi. In turn, this may increase the efficiency of the cough reflex and facilitate removal of the secretions. Guaifenesin is over-the-counter drug for the treatment of cough and common cold.

Read about Guaifenesin
3 Pseudoephedrine
UNII 6V9V2RYJ8N - PSEUDOEPHEDRINE HYDROCHLORIDE

Pseudoephedrine is a sympathomimetic agent with direct and indirect effects on adrenergic receptors. It has alpha and beta adrenergic activity and some stimulant effect on the central nervous system. The sympathomimetic effect of pseudoephedrine produces vasoconstriction which in turn relieves nasal congestion.

Read about Pseudoephedrine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
R01BA52 Pseudoephedrine, combinations R Respiratory system → R01 Nasal preparations → R01B Nasal decongestants for systemic use → R01BA Sympathomimetics
Discover more medicines within R01BA52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EC Agencia Nacional de Regulaciรณn, Control y Vigilancia Sanitaria Identifier(s): 8.190-1-06-04

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.